Omalizumab's efficacy and safety against chronic spontaneous urticaria

I have read the article titled, "Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China", by Wang et al with great interest. Nevertheless, there are a couple of questions raised in my mind. And clarification of some aspects of the study will he...

Descripción completa

Detalles Bibliográficos
Autor principal: Özdemir, Öner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458888/
https://www.ncbi.nlm.nih.gov/pubmed/37638362
http://dx.doi.org/10.1016/j.waojou.2023.100808
_version_ 1785097274538328064
author Özdemir, Öner
author_facet Özdemir, Öner
author_sort Özdemir, Öner
collection PubMed
description I have read the article titled, "Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China", by Wang et al with great interest. Nevertheless, there are a couple of questions raised in my mind. And clarification of some aspects of the study will help the reader benefit and have a better understanding of the study.
format Online
Article
Text
id pubmed-10458888
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher World Allergy Organization
record_format MEDLINE/PubMed
spelling pubmed-104588882023-08-27 Omalizumab's efficacy and safety against chronic spontaneous urticaria Özdemir, Öner World Allergy Organ J Correspondence I have read the article titled, "Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China", by Wang et al with great interest. Nevertheless, there are a couple of questions raised in my mind. And clarification of some aspects of the study will help the reader benefit and have a better understanding of the study. World Allergy Organization 2023-08-17 /pmc/articles/PMC10458888/ /pubmed/37638362 http://dx.doi.org/10.1016/j.waojou.2023.100808 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Correspondence
Özdemir, Öner
Omalizumab's efficacy and safety against chronic spontaneous urticaria
title Omalizumab's efficacy and safety against chronic spontaneous urticaria
title_full Omalizumab's efficacy and safety against chronic spontaneous urticaria
title_fullStr Omalizumab's efficacy and safety against chronic spontaneous urticaria
title_full_unstemmed Omalizumab's efficacy and safety against chronic spontaneous urticaria
title_short Omalizumab's efficacy and safety against chronic spontaneous urticaria
title_sort omalizumab's efficacy and safety against chronic spontaneous urticaria
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458888/
https://www.ncbi.nlm.nih.gov/pubmed/37638362
http://dx.doi.org/10.1016/j.waojou.2023.100808
work_keys_str_mv AT ozdemironer omalizumabsefficacyandsafetyagainstchronicspontaneousurticaria

Ejemplares similares